Supported by the experimental data, we demonstrated the clinical significance of TBL1X and Flot2 as biomarkers of NPC metastasis, which supports their high targeted therapeutic value for NPC patients. This evidence concerns the gene FLOT2 and nasopharyngeal carcinoma.